---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000048"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:36:45.666810+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics expects Q3 2024 revenue of $210-212M, reaffirms FY2024 guidance

## Summary
- Preliminary Q3 2024 revenue expected between $210M and $212M.
- Full-year 2024 revenue guidance reaffirmed at $835M-$845M.
- Divestiture of EndoPredict business in Europe closed on August 1, 2024.
- Results are preliminary and unaudited; subject to finalization.

## SEC filing metadata
- accession: 0000899923-24-000048
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000048/0000899923-24-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000048/mygn-20241009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000048
- JSON: https://secwatch.observer/filing/0000899923-24-000048.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.